Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States.
Mol Pharm. 2023 Nov 6;20(11):5454-5462. doi: 10.1021/acs.molpharmaceut.3c00175. Epub 2023 Oct 2.
Phosphatidylserine (PS) is an anionic phospholipid component in endogenous high-density lipoprotein (HDL). With the intrinsic anti-inflammatory effects of PS and the correlation between PS content and HDL functions, it was hypothesized that incorporating PS would enhance the therapeutic effects of HDL mimetic particles. To test this hypothesis, a series of synthetic high-density lipoproteins (sHDLs) were prepared with an apolipoprotein A-I (ApoA-1) mimetic peptide, 1-palmitoyl-2-oleoyl--3-phosphocholine (POPC), and 1-palmitoyl-2-oleoyl--3-phospho-l-serine (POPS). Incorporating PS was found to improve the particle stability of sHDLs. Moreover, increasing the PS content in sHDLs enhanced the anti-inflammatory effects on lipopolysaccharide-activated macrophages and endothelial cells. The incorporation of PS had no negative impact on cholesterol efflux capacity, cholesterol mobilization, and did not affect the pharmacokinetic profiles of sHDLs. Such results suggest the therapeutic potential of PS-containing sHDLs for inflammation resolution in atherosclerosis and other inflammatory diseases.
磷脂酰丝氨酸(PS)是内源性高密度脂蛋白(HDL)中的一种阴离子磷脂成分。由于 PS 具有内在的抗炎作用,以及 PS 含量与 HDL 功能之间的相关性,因此假设将 PS 掺入其中会增强 HDL 模拟颗粒的治疗效果。为了验证这一假设,用载脂蛋白 A-I(ApoA-1)模拟肽 1-棕榈酰基-2-油酰基--3-磷酸胆碱(POPC)和 1-棕榈酰基-2-油酰基--3-磷酸丝氨酸(POPS)制备了一系列合成高密度脂蛋白(sHDL)。结果发现,掺入 PS 可提高 sHDL 的颗粒稳定性。此外,增加 sHDL 中的 PS 含量可增强对脂多糖激活的巨噬细胞和内皮细胞的抗炎作用。PS 的掺入对胆固醇外排能力、胆固醇动员没有负面影响,也不影响 sHDL 的药代动力学特征。这些结果表明,含 PS 的 sHDL 具有治疗动脉粥样硬化和其他炎症性疾病中炎症消退的潜力。